Drugs

New Safety Measures Announced for Immediate Release (IR) Opioids

[3-22-16] In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse and abuse, which can lead to addiction, overdose and death. Today’s actions are among a number of steps the Agency recently outlined in a plan to reassess its approach to opioid medications. The plan is focused on policies aimed at reversing the prescription opioid abuse epidemic, while still providing patients in pain access to effective relief.

 
The FDA is also requiring several additional safety labeling changes across all prescription opioid products to include additional information on the risk of these medications.  This is part of the agency’s overall effort to help inform prescribers about the importance of balancing the serious risks of opioids with their role in managing pain.

 

March 22, 2016

 

Resources for You

Page Last Updated: 03/22/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English